Sergio Waxman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergio Waxman has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Fumiyuki Ishibashi
Lahey Clinic Department of Cardiovascular Medicine 41 Mall Rd Burlington Mass USA
5 shared publicationsAlexandra Dabreo
Tufts-New England Medical Center
3 shared publicationsJames E. Muller
InfraReDx, Inc., Burlington, Massachusetts
3 shared publicationsCathy Jeon
Lahey Clinic 41 Burlington Mall Road, 5 East, Cardiovascular Medicine Burlington Massachusetts
2 shared publications- Thomas Piemonte
Lahey Clinic 41 Burlington Mall Road, 5 East, Cardiovascular Medicine Burlington Massachusetts
2 shared publications Adam J. Saltzman
Division of Cardiology, Center for Translational Cardiovascular Research, Tufts‐New England Medical Center, Boston, Massachusetts
1 shared publication
Latest Publications
- 21 November 2017
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 167 (10) , 752
2:32 a.m.
- 21 November 2017
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 167 (10) , 752
2:32 a.m.
- 1 April 2017
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 18 (3) , 212
Congenital single coronary artery: A rare anatomic variant
- 1 April 2017
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 18 (3) , 212
Congenital single coronary artery: A rare anatomic variant
- 9 November 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 84 (1) , 70-74
Right heart catheterization using antecubital venous access: Feasibility, safety and adoption rate in a tertiary center
Objectives: To determine feasibility, safety, and adoption rates of right heart catheterization (RHC) using antecubital venous access (AVA) as compared to using the traditional approach of proximal venous access (PVA).Background: RHC via PVA (i.e., internal jugular, femoral or subclavian) is generally a low risk procedure; however, complications may occur and are usually access site related. RHC via an antecubital approach has regained attention given the increase in transradial left heart catheterizations.Methods: Patients undergoing RHC for any indication at a single large academic medical center were identified over a 5‐year period (January 2008 to December 2012) from a database. Medical records were retrospectively analyzed for demographic, procedural and outcomes data.Results: Two hundred seventy‐two RHC procedures were included (106 AVA, 166 PVA). The adoption rate of AVA for RHC increased rapidly since its introduction in our laboratory in 2010 (100% PVA in 2008 and 2009, 85% AVA in 2012). All procedures were successful; however, 6% of procedures required additional, alternate access to the original site. Initial success rates were similar in the two groups (91 vs. 96% for AVA and PVA respectively, P = 0.12). Fluoroscopy time was shorter in the group of patients who underwent the procedure via AVA. The complication rate was 0% in the AVA group compared with 3% in the PVA group (P = 0.16).Conclusion: RHC via the AVA is a feasible and safe alternative to PVA. Our experience and rapid adoption support the use AVA as the access site of choice for RHC in uncomplicated patients.
- 9 November 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 84 (1) , 70-74
Right heart catheterization using antecubital venous access: Feasibility, safety and adoption rate in a tertiary center
Objectives: To determine feasibility, safety, and adoption rates of right heart catheterization (RHC) using antecubital venous access (AVA) as compared to using the traditional approach of proximal venous access (PVA).Background: RHC via PVA (i.e., internal jugular, femoral or subclavian) is generally a low risk procedure; however, complications may occur and are usually access site related. RHC via an antecubital approach has regained attention given the increase in transradial left heart catheterizations.Methods: Patients undergoing RHC for any indication at a single large academic medical center were identified over a 5‐year period (January 2008 to December 2012) from a database. Medical records were retrospectively analyzed for demographic, procedural and outcomes data.Results: Two hundred seventy‐two RHC procedures were included (106 AVA, 166 PVA). The adoption rate of AVA for RHC increased rapidly since its introduction in our laboratory in 2010 (100% PVA in 2008 and 2009, 85% AVA in 2012). All procedures were successful; however, 6% of procedures required additional, alternate access to the original site. Initial success rates were similar in the two groups (91 vs. 96% for AVA and PVA respectively, P = 0.12). Fluoroscopy time was shorter in the group of patients who underwent the procedure via AVA. The complication rate was 0% in the AVA group compared with 3% in the PVA group (P = 0.16).Conclusion: RHC via the AVA is a feasible and safe alternative to PVA. Our experience and rapid adoption support the use AVA as the access site of choice for RHC in uncomplicated patients.
- 3 September 2010
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 3 (6) , 403-411
Catheter-Based Near-Infrared Spectroscopy for Imaging of Lipid-Rich Plaques
- 3 September 2010
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 3 (6) , 403-411
Catheter-Based Near-Infrared Spectroscopy for Imaging of Lipid-Rich Plaques
- 4 August 2009
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 2 (4) , 300-306
Intracoronary thermography: Utility to detect vulnerable and culprit plaques in patients with coronary artery disease
- 4 August 2009
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 2 (4) , 300-306
Intracoronary thermography: Utility to detect vulnerable and culprit plaques in patients with coronary artery disease
- 1 July 2009
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 2 (7) , 858-868
In Vivo Validation of a Catheter-Based Near-Infrared Spectroscopy System for Detection of Lipid Core Coronary Plaques
- 1 July 2009
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 2 (7) , 858-868
In Vivo Validation of a Catheter-Based Near-Infrared Spectroscopy System for Detection of Lipid Core Coronary Plaques
- 18 November 2008
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 21 (6) , 452-458
Near‐Infrared Spectroscopy for Plaque Characterization
A near‐infrared (NIR) spectroscopy catheter‐based system has been developed for intracoronary detection of lipid‐rich plaques, capable of scanning an artery through blood and during cardiac motion. The lipid‐rich plaque chemometric algorithm was validated in an ex vivo study using coronary artery specimens from autopsy hearts. A parallel clinical study was performed to demonstrate safety of the system in patients and the similarity of spectra acquired in vivo to data from the ex vivo study. Proof of spectral similarity between data obtained in patients and data from autopsy specimens is required to demonstrate the applicability of the algorithm to patients, in whom tissue for analysis is not available. A preliminary analysis in an unblinded cohort of patients from the clinical study reported promising results. The final results of the clinical study will be submitted for publication. The potential clinical value of this NIR spectroscopy device is discussed.
- 18 November 2008
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 21 (6) , 452-458
Near‐Infrared Spectroscopy for Plaque Characterization
A near‐infrared (NIR) spectroscopy catheter‐based system has been developed for intracoronary detection of lipid‐rich plaques, capable of scanning an artery through blood and during cardiac motion. The lipid‐rich plaque chemometric algorithm was validated in an ex vivo study using coronary artery specimens from autopsy hearts. A parallel clinical study was performed to demonstrate safety of the system in patients and the similarity of spectra acquired in vivo to data from the ex vivo study. Proof of spectral similarity between data obtained in patients and data from autopsy specimens is required to demonstrate the applicability of the algorithm to patients, in whom tissue for analysis is not available. A preliminary analysis in an unblinded cohort of patients from the clinical study reported promising results. The final results of the clinical study will be submitted for publication. The potential clinical value of this NIR spectroscopy device is discussed.
- 1 June 2008
- Vol. 20 (6) , 319-22
Single-center experience with the TandemHeart percutaneous ventricular assist device to support patients undergoing high-risk percutaneous coronary intervention.
We describe our experience of patients, from December 2005 through May 2007 who underwent percutaneous coronary intervention (PCI) with severely depressed left ventricle systolic function and complex coronary lesions. The complex coronary lesions included multiple vessel coronary artery disease, left main (LM) coronary artery disease, calcified coronary lesions and bypass graft disease. All patients were clinically assessed to be at too high of a risk for circulatory collapse without maximal hemodynamic support while they underwent high-risk PCI. The TandemHeart percutaneous ventricular assist device (THpVAD) may be able to provide the necessary circulatory support required to enhance procedural success and patient safety during high-risk PCI. We implanted the THpVAD in 6 patients who underwent high-risk PCI. There was unanimity among several physicians in our institution that each patient was an exceptionally high risk for circulatory collapse due to the anticipated procedural complexity. The average ejection fraction was 33% (range 15-65%). Five of the patients were considered to be at an unacceptably high risk for coronary artery bypass surgery. All 6 patients underwent multivessel PCI. Five of the 6 underwent unprotected LM PCI. One patient of the 5 underwent vein-graft PCI as well as a debulking procedure with rotational atherectomy and PCI of the LM. We had a 100% success rate with implantation of the THpVAD. Five of the 6 patients were alive at 30 days post procedure. One patient died 3 days after the procedure due to multiorgan failure. A vascular surgeon performed the removal of the devices with no associated complications. Our clinical experiences with the TandemHeart pVAD demonstrated that hemodynamic support could be achieved safely, efficiently and effectively by way of a percutaneous route in anticipation of high-risk PCI.
- 1 June 2008
- Vol. 20 (6) , 319-22
Single-center experience with the TandemHeart percutaneous ventricular assist device to support patients undergoing high-risk percutaneous coronary intervention.
We describe our experience of patients, from December 2005 through May 2007 who underwent percutaneous coronary intervention (PCI) with severely depressed left ventricle systolic function and complex coronary lesions. The complex coronary lesions included multiple vessel coronary artery disease, left main (LM) coronary artery disease, calcified coronary lesions and bypass graft disease. All patients were clinically assessed to be at too high of a risk for circulatory collapse without maximal hemodynamic support while they underwent high-risk PCI. The TandemHeart percutaneous ventricular assist device (THpVAD) may be able to provide the necessary circulatory support required to enhance procedural success and patient safety during high-risk PCI. We implanted the THpVAD in 6 patients who underwent high-risk PCI. There was unanimity among several physicians in our institution that each patient was an exceptionally high risk for circulatory collapse due to the anticipated procedural complexity. The average ejection fraction was 33% (range 15-65%). Five of the patients were considered to be at an unacceptably high risk for coronary artery bypass surgery. All 6 patients underwent multivessel PCI. Five of the 6 underwent unprotected LM PCI. One patient of the 5 underwent vein-graft PCI as well as a debulking procedure with rotational atherectomy and PCI of the LM. We had a 100% success rate with implantation of the THpVAD. Five of the 6 patients were alive at 30 days post procedure. One patient died 3 days after the procedure due to multiorgan failure. A vascular surgeon performed the removal of the devices with no associated complications. Our clinical experiences with the TandemHeart pVAD demonstrated that hemodynamic support could be achieved safely, efficiently and effectively by way of a percutaneous route in anticipation of high-risk PCI.
- 1 September 2007
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 14 (5) , 719-728
Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques
- 1 September 2007
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 14 (5) , 719-728
Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques